OncoMatch/Clinical Trials/NCT07651124
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Is NCT07651124 recruiting? Yes, currently enrolling (Jul 2026). This NA trial studies non-drug interventions for recurrent ovarian cancer.
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07651124 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages